Opioid, Benzodiazepine and Alcohol Withdrawal

The answer first

Alcohol, benzodiazepine and opioid withdrawal are three distinct neuroadaptive syndromes that share a common principle: abrupt cessation of a chronically ingested central nervous system depressant unmasks compensatory upregulation of excitatory pathways, producing the autonomic, neuropsychiatric and gastrointestinal features that frame every withdrawal assessment. [1] Alcohol and benzodiazepine withdrawal are managed with γ-aminobutyric acid (GABA)-ergic replacement and gradual taper because they are the two syndromes that can kill; opioid withdrawal is intensely distressing and occasionally dangerous in the frail or pregnant patient but is rarely fatal in isolation, and the first-line agent is a partial μ-agonist, not a benzodiazepine. [4]

A physician-level answer rests on four pillars. [1]

1. Identify the substance, quantify risk and exclude mimics — confirm with collateral history and urine drug screen; stratify risk with PAWSS (Prediction of Alcohol Withdrawal Severity Scale) for alcohol, the Clinical Opiate Withdrawal Scale (COWS) for opioids, and a careful benzodiazepine exposure history; rule out sepsis, intracranial haemorrhage, hepatic encephalopathy, hypoglycaemia and toxic alcohol co-ingestion, all of which mimic or complicate withdrawal. [3]
2. Prevent the dangerous complications early — give parenteral thiamine before any glucose in every alcohol-withdrawing patient; treat seizures with lorazepam; identify benzodiazepine-resistant withdrawal before autonomic collapse; and have naloxone accessible wherever opioids may be present. [3]
3. Use the right scale to drive therapy — CIWA-Ar (Clinical Institute Withdrawal Assessment–Alcohol revised) for symptom-triggered benzodiazepine dosing in mild–moderate alcohol withdrawal; COWS to time buprenorphine induction; and a written taper schedule for benzodiazepine withdrawal rather than an as-needed approach. [2]
4. Bridge every admission to long-term relapse-prevention pharmacotherapy — naltrexone or acamprosate for alcohol use disorder, buprenorphine or methadone maintenance for opioid use disorder, and a structured benzodiazepine taper plus cognitive–behavioural therapy for benzodiazepine dependence; without this bridge, readmission within 30 days is the rule. [8] [10]

DWE high-yield: The single most tested action in alcohol withdrawal is parenteral thiamine before glucose. Pabrinex (high-dose B vitamins) 1 pair intravenously daily for 3 to 5 days, then oral thiamine, prevents Wernicke encephalopathy. Intravenous glucose given before thiamine in a deficient patient precipitates acute Wernicke by exhausting the last thiamine-dependent steps of the Krebs cycle. [1] [4]

References12Show ledgerHide ledger

1. [1]Kast KA, Sidelnik SA, Nejad SH, et al. Management of alcohol withdrawal syndromes in general hospital settings. BMJ, 2025.PMID 39778965
2. [2]Holleck JL, Merchant N, Gunderson CG Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. J Gen Intern Med, 2019.PMID 30937668
3. [3]Dixit D, Endicott J, Burry L, et al. Management of Acute Alcohol Withdrawal Syndrome in Critically Ill Patients. Pharmacotherapy, 2016.PMID 27196747
4. [4]Manasco A, Chang S, Larriviere J, et al. Alcohol withdrawal. South Med J, 2012.PMID 23128805
5. [5]Tidwell WP, Thomas TL, Pouliot JD, et al. Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. Am J Crit Care, 2018.PMID 30385536
6. [6]Kessel KM, Olson LM, Kruse DA, et al. Phenobarbital Versus Benzodiazepines for the Treatment of Severe Alcohol Withdrawal. Ann Pharmacother, 2024.PMID 38247044
7. [7]Shah P, Stegner-Smith KL, Rachid M, et al. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. J Med Toxicol, 2022.PMID 35668289
8. [8]Kranzler HR, Soyka M Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA, 2018.PMID 30167705
9. [9]McPheeters M, O'Connor EA, Riley S, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA, 2023.PMID 37934220
10. [10]Shulman M, Wai JM, Nunes EV Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs, 2019.PMID 31062259
11. [11]Britch SC, Walsh SL Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology (Berl), 2022.PMID 35385972
12. [12]Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev, 2018.PMID 29543325